Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?

Eric K Nakakura; Alan P Venook; Emily K Bergsland

doi:10.1016/j.soc.2007.04.019

Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?

Surg Oncol Clin N Am. 2007 Jul;16(3):639-51, x. doi: 10.1016/j.soc.2007.04.019.

Authors

Eric K Nakakura¹, Alan P Venook, Emily K Bergsland

Affiliation

¹ Department of Surgery, Division of Surgical Oncology, University of California, UCSF Comprehensive Cancer Center, 1600 Divisadero Street, A-724, San Francisco, CA 94143-1932, USA.

PMID: 17606198
DOI: 10.1016/j.soc.2007.04.019

Abstract

A multidisciplinary team is essential for the optimal management of patients with metastatic neuroendocrine tumors. In this article, the systemic and regional nonsurgical therapeutic options for metastatic neuroendocrine cancers are discussed. In particular, the roles of biotherapy, chemotherapy, and hepatic artery embolization/chemoembolization are reviewed. A proposed treatment algorithm is provided with the aim of providing clinicians with a useful framework for managing these challenging patients. Finally, the rationale for promising investigational therapies is described.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use
Chemoembolization, Therapeutic
Hepatic Artery
Humans
Liver Neoplasms / diagnosis
Liver Neoplasms / secondary
Liver Neoplasms / therapy
Neoplasm Metastasis
Neuroendocrine Tumors / diagnosis
Neuroendocrine Tumors / secondary*
Neuroendocrine Tumors / therapy*

Substances

Antineoplastic Agents